Analysts Anticipate Reata Pharmaceuticals Inc (NASDAQ:RETA) Will Post Quarterly Sales of $6.50 Million

Analysts expect Reata Pharmaceuticals Inc (NASDAQ:RETA) to announce $6.50 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.24 million and the lowest estimate coming in at $2.50 million. Reata Pharmaceuticals reported sales of $8.45 million in the same quarter last year, which indicates a negative year-over-year growth rate of 23.1%. The company is scheduled to report its next earnings report after the market closes on Wednesday, February 19th.

According to Zacks, analysts expect that Reata Pharmaceuticals will report full year sales of $30.33 million for the current fiscal year, with estimates ranging from $26.35 million to $32.09 million. For the next financial year, analysts anticipate that the firm will report sales of $44.15 million, with estimates ranging from $900,000.00 to $114.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.07). Reata Pharmaceuticals had a negative net margin of 398.84% and a negative return on equity of 3,281.61%. The business had revenue of $8.24 million during the quarter, compared to analyst estimates of $7.43 million. During the same quarter in the prior year, the company earned ($1.07) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis.

Several equities analysts recently weighed in on the stock. Citigroup increased their price objective on shares of Reata Pharmaceuticals from $241.00 to $328.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. Stifel Nicolaus restated a “buy” rating and issued a $305.00 price objective (up from $210.00) on shares of Reata Pharmaceuticals in a report on Thursday, November 14th. Robert W. Baird increased their price objective on shares of Reata Pharmaceuticals from $162.00 to $245.00 and gave the company a “positive” rating in a report on Tuesday, November 12th. ValuEngine lowered shares of Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Finally, National Securities lowered shares of Reata Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, November 13th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $255.63.

In other Reata Pharmaceuticals news, CAO Elaine Castellanos sold 2,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $194.24, for a total value of $388,480.00. Following the sale, the chief accounting officer now directly owns 17,146 shares in the company, valued at $3,330,439.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jason Douglas Wilson sold 10,000 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $203.26, for a total transaction of $2,032,600.00. Following the completion of the sale, the vice president now owns 17,350 shares in the company, valued at $3,526,561. The disclosure for this sale can be found here. Company insiders own 34.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE raised its holdings in Reata Pharmaceuticals by 1,533.3% in the fourth quarter. US Bancorp DE now owns 245 shares of the company’s stock worth $50,000 after purchasing an additional 230 shares during the period. Lindbrook Capital LLC acquired a new stake in shares of Reata Pharmaceuticals during the third quarter worth $32,000. Tower Research Capital LLC TRC raised its holdings in shares of Reata Pharmaceuticals by 1,603.1% during the third quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock worth $44,000 after acquiring an additional 513 shares during the period. Americana Partners LLC acquired a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth $122,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth $124,000. Institutional investors own 59.80% of the company’s stock.

NASDAQ RETA traded down $4.37 during trading hours on Friday, hitting $225.65. The company’s stock had a trading volume of 180,743 shares, compared to its average volume of 387,105. The stock has a fifty day moving average of $211.92 and a 200 day moving average of $157.75. Reata Pharmaceuticals has a twelve month low of $70.00 and a twelve month high of $257.96. The firm has a market capitalization of $6.83 billion, a P/E ratio of -52.48 and a beta of 2.58.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Featured Article: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.